[Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics]. [PDF]
Liang G +8 more
europepmc +1 more source
[Progress in clinical research related to viral hepatitis in 2025]. [PDF]
Ding Y, Li Y, Dou XG.
europepmc +1 more source
[New Landscape in the Treatment of Limited-stage Small Cell Lung Cancer: From Conventional Chemoradiotherapy to Latest Advances in Precision Medicine]. [PDF]
Han J, Dai K, Meng Z, Huang J.
europepmc +1 more source
[Research progress on toxic shock syndrome due to group A <i>Streptococcus</i> infection in children]. [PDF]
Wang HY, Zhou W, Huang LS.
europepmc +1 more source
[<i>Shengmai San</i> improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway]. [PDF]
Liang Z +6 more
europepmc +1 more source
[Chinese Expert Consensus on Clinical Management of Oncogene Addicted Non-small Cell Lung Cancer with Leptomeningeal Metastasis (2026 Edition)]. [PDF]
Lung Cancer Medical Education Committee of Chinese Medical Education Association +2 more
europepmc +1 more source
[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis]. [PDF]
Chen X +11 more
europepmc +1 more source
[Clinical research advances for small-molecule nucleic acid drugs in the treatment of chronic hepatitis B]. [PDF]
Wang WX +4 more
europepmc +1 more source
[Research Progress on Glycolytic Reprogramming and Lactylation Crosstalk in Tumors]. [PDF]
Feng Y +9 more
europepmc +1 more source
[SERPINE1 overexpression promotes proliferation and paclitaxel resistance of triple-negative breast cancer cells by inducing M2 macrophage polarization]. [PDF]
Zhang Q +10 more
europepmc +1 more source

